Thiazolidinediones Are Partial Agonists for the Glucocorticoid ReceptorMATTHEWS, L; BERRY, A; TERSIGNI, M et al.Endocrinology (Philadelphia). 2009, Vol 150, Num 1, pp 75-86, issn 0013-7227, 12 p.Article

The Antagonists But Not Partial Agonists of Glucocorticoid Receptor Ligands Show Substantial Side Effect DissociationXIAO HU; SARAH DU; HEGDE, Shridhar G et al.Endocrinology (Philadelphia). 2011, Vol 152, Num 8, pp 3123-3134, issn 0013-7227, 12 p.Article

U-80816 : a novel partial muscarinic agonistSETHY, V. H; FRANCIS, J. W; PIERCEY, M. F et al.Drug development research. 1991, Vol 24, Num 1, pp 53-66, issn 0272-4391Article

Review article: tegaserod: the global experienceCHEY, W. D.Alimentary pharmacology & therapeutics. Supplement. 2004, Vol 20, Num 7, pp 15-19, issn 0953-0673, 5 p.Article

The preferential dopamine D₃ receptor ligand, (+)-UH232, is a partial agonistGRIFFON, N; PILON, C; SCHWARTZ, J.-C et al.European journal of pharmacology. 1995, Vol 282, Num 1-3, pp R3-R4, issn 0014-2999Article

A Perioperative Smoking Cessation Intervention with Varenicline: A Double-blind, Randomized, Placebo-controlled TrialWONG, Jean; ABRISHAMI, Amir; YILIANG YANG et al.Anesthesiology (Philadelphia). 2012, Vol 117, Num 4, pp 755-764, issn 0003-3022, 10 p.Article

Partial dopamine agonists in the treatment of psychosisTAMMINGA, C. A.Journal of neural transmission. 2002, Vol 109, Num 3, pp 411-420, issn 0300-9564Article

A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypesSAKAMOTO, Junichi; KIMURA, Hiroyuki; MORIYAMA, Shinji et al.European journal of pharmacology. 2004, Vol 495, Num 1, pp 17-26, issn 0014-2999, 10 p.Article

Non-prostanoid prostacyclin mimetics. VI: Derivatives of 2-[3-[2-(4,5-diphenyl-2-oxazolyl)ethyl]phenoxy]acetic acid modified β-to the oxazole ringMEANWELL, N. A; ROSENFELD, M. J; ZAVOICO, G. B et al.Drug design and discovery (Print). 1994, Vol 11, Num 1, pp 73-89, issn 1055-9612Article

Determination of the functional dissociation constant of a partial agonist by comparison with a higher efficacy agonistFREEMAN, K. A; TALLARIDA, R. J.Journal of pharmacological methods. 1991, Vol 25, Num 1, pp 11-18, issn 0160-5402, 8 p.Article

Vilazodone: Clinical Basis for the US Food and Drug Administration's Approval of a New AntidepressantLAUGHREN, Thomas P; GOBBURU, Jogarao; LEVIN, Robert L et al.The Journal of clinical psychiatry. 2011, Vol 72, Num 9, pp 1166-1173, issn 0160-6689, 8 p.Article

Identification and optimization of novel partial agonists of Neuromedin B receptor using parallel synthesisSHUTTLEWORTH, Stephen J; LIZARZABURU, Mike E; CHAI, Anne et al.Bioorganic & medicinal chemistry letters (Print). 2004, Vol 14, Num 12, pp 3037-3042, issn 0960-894X, 6 p.Article

Antipsychotic effects of bretazenil, a partial benzodiazepine agonist in acute schizophrenia : A study group reportDELINI-STULA, A; BERDAH-TORDJMAN, D.Journal of psychiatric research. 1996, Vol 30, Num 4, pp 239-250, issn 0022-3956Article

Antidepressant activity of buspirone in anxietyALLMANN, B. J. C; DOMANTAY, A; SCHOEMAN, H. S et al.Current therapeutic research. 1992, Vol 52, Num 3, pp 406-411, issn 0011-393XArticle

Pharmacokinetics of the partial β-agonist doxaminol in dogNEIDLEIN, R; VOLLAND, C; STREIN, K et al.Arzneimittel-Forschung. 1990, Vol 40, Num 1, pp 27-31, issn 0004-4172Article

The Glycogen Synthase Kinase Inhibitor 3-(2,4-Dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione (SB216763) Is a Partial Agonist of the Aryl Hydrocarbon ReceptorBRAEUNING, Albert; BUCHMANN, Albrecht.Drug metabolism and disposition. 2009, Vol 37, Num 8, pp 1576-1580, issn 0090-9556, 5 p.Article

Modulation of intestinal gas dynamics in healthy human volunteers by the 5-HT₄ receptor agonist tegaserodCOLESKI, Radoslav; OWYANG, Chung; HASLER, William L et al.The American journal of gastroenterology. 2006, Vol 101, Num 8, pp 1858-1865, issn 0002-9270, 8 p.Article

Induction of depersonalization by the serotonin agonist meta-chlorophenylpiperazineSIMEON, D; HOLLANDER, E; STEIN, D. J et al.Psychiatry research. 1995, Vol 58, Num 2, pp 161-164, issn 0165-1781Article

Design and synthesis of azabicyclic muscarinic agonists incorporating an oxime ether functionalityBROMIDGE, S. M; BROWN, F; CASSIDY, F et al.Cholinomimetics and Alzheimer's disease. Bioorganic & medicinal chemistry letters. 1992, Vol 2, Num 8, pp 787-790Book Chapter

Buspirone does not produce a 5-HT_1A-mediated decrease in temperature in manLEE, H. S; MELTZER, H. Y.Journal of neural transmission. 1991, Vol 86, Num 1, pp 71-76, issn 0300-9564Article

On the central effects of a new partial benzodiazepine agonist RO 16-6028 in man: pharmaco-EEG and psychometric studiesSALETU, B; GRUNBERGER, J; LINZMAYER, L et al.International journal of clinical pharmacology, therapy and toxicology (1980). 1989, Vol 27, Num 2, pp 51-65, issn 0174-4879Article

Perspectives actuelles des benzodiazépines = Currents prospects of benzodiazepinesGUT, J. P; LAURENT, J. P; MERZ, W. A et al.Thérapie (Paris). 1986, Vol 41, Num 1, pp 31-35, issn 0040-5957Conference Paper

Sentiment Analysis to Determine the Impact of Online Messages on Smokers' Choices to Use VareniclineCOBB, Nathan K; MAYS, Darren; GRAHAM, Amanda L et al.Journal of the National Cancer Institute. Monographs. 2013, Vol 47, pp 224-230, issn 1052-6773, 7 p.Article

Effects of Varenicline on Smoking Cue-Triggered Neural and Craving ResponsesFRANKLIN, Teresa; ZE WANG; SUH, Jesse J et al.Archives of general psychiatry. 2011, Vol 68, Num 5, pp 516-526, issn 0003-990X, 11 p.Article

Tegaserod Treatment for Dysmotility-Like Functional Dyspepsia : Results of two Randomized Controlled TrialsVAKIL, Nimish; LAINE, Loren; TALLEY, Nicholas J et al.The American journal of gastroenterology. 2008, Vol 103, Num 8, pp 1906-1919, issn 0002-9270, 14 p.Article